PL1651248T3 - Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej - Google Patents

Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej

Info

Publication number: PL1651248T3
Authority: PL; Poland
Prior art keywords: pharmaceutical compositions; delivery agent; pharmacologically active; micronized form; orally dosed
Prior art date: 2003-07-11

Application number

PL04740863T

Other languages

English (en)

Inventor

Shoufeng Li

Anasuya Ashok Ghosh

Simon David Bateman

Moise Azria

Alan Edward Royce

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-11

Filing date

2004-07-09

Publication date

2010-02-26

2004-07-09 Application filed by Novartis Ag filed Critical Novartis Ag

2010-02-26 Publication of PL1651248T3 publication Critical patent/PL1651248T3/pl

Links

229940124447 delivery agent Drugs 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000013543 active substance Substances 0.000 abstract 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 2
102000055006 Calcitonin Human genes 0.000 abstract 1
108060001064 Calcitonin Proteins 0.000 abstract 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
229960004015 calcitonin Drugs 0.000 abstract 1
229960000913 crospovidone Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
229940069328 povidone Drugs 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Physical Education & Sports Medicine (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Permanent Magnet Type Synchronous Machine (AREA)

PL04740863T 2003-07-11 2004-07-09 Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej PL1651248T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US48649503P	2003-07-11	2003-07-11
EP04740863A EP1651248B1 (en)	2003-07-11	2004-07-09	Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
PCT/EP2004/007584 WO2005004900A1 (en)	2003-07-11	2004-07-09	Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Publications (1)

Publication Number	Publication Date
PL1651248T3 true PL1651248T3 (pl)	2010-02-26

Family

ID=34062133

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04740863T PL1651248T3 (pl)	2003-07-11	2004-07-09	Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej

Country Status (14)

Country	Link
US (3)	US20070065505A1 (pl)
EP (1)	EP1651248B1 (pl)
JP (1)	JP5032844B2 (pl)
CN (1)	CN1809377B (pl)
AT (1)	ATE442158T1 (pl)
AU (1)	AU2004255458B2 (pl)
BR (1)	BRPI0412458A (pl)
CA (1)	CA2529604C (pl)
DE (1)	DE602004023093D1 (pl)
ES (1)	ES2330638T3 (pl)
MX (1)	MXPA06000446A (pl)
PL (1)	PL1651248T3 (pl)
PT (1)	PT1651248E (pl)
WO (1)	WO2005004900A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60233803D1 (de) *	2001-08-17	2009-11-05	Novartis Ag	5-cnac zur oralen verabreichung von parathormonfragmenten
US20060078623A1 (en) *	2004-08-13	2006-04-13	Emisphere Technologies, Inc.	Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
PE20070548A1 (es) *	2005-09-19	2007-07-12	Emisphere Tech Inc	Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
GB0522566D0 (en) *	2005-11-04	2005-12-14	Novartis Ag	Organic compounds
EP2059260B1 (en) *	2006-08-31	2013-06-19	Novartis AG	Pharmaceutical compositions comprising hGH for oral delivery
AR062925A1 (es) *	2006-09-22	2008-12-17	Novartis Ag	Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
US8022048B2 (en) *	2007-11-02	2011-09-20	Emisphere Technologies, Inc.	Method of treating vitamin B12 deficiency
EP2538945A4 (en) *	2010-02-24	2013-07-24	Emisphere Tech Inc	Oral b12 therapy
MX377589B (es)	2010-12-16	2025-03-10	Novo Nordisk As	Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en)	2011-04-12	2015-12-03	Novo Nordisk A/S	Double-acylated GLP-1 derivatives
KR102072202B1 (ko)	2012-03-22	2020-01-31	노보 노르디스크 에이/에스	Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
ES2715308T3 (es)	2012-03-22	2019-06-03	Novo Nordisk As	Composiciones que comprenden un agente de suministro y su preparación
HUE064694T2 (hu)	2012-03-22	2024-04-28	Novo Nordisk As	Továbbítószert tartalmazó készítmények és elõállításuk
WO2013189988A1 (en)	2012-06-20	2013-12-27	Novo Nordisk A/S	Tablet formulation comprising a peptide and a delivery agent
RS58039B1 (sr)	2013-05-02	2019-02-28	Novo Nordisk As	Oralno doziranje glp-1 jedinjenja
CN104095828A (zh) *	2014-07-29	2014-10-15	中国药科大学	一种降钙素口服肠溶组合物及其制备方法
AR114353A1 (es)	2018-02-02	2020-08-26	Novo Nordisk As	Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
WO2021050697A1 (en) *	2019-09-11	2021-03-18	Barlean's Organic Oils, Llc	Softgel fill materials
CR20230308A (es)	2020-12-11	2023-09-08	Civi Biopharma Inc	Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
MX2023012437A (es)	2021-04-22	2023-11-07	Civi Biopharma Inc	Administracion oral de oligonucleotidos.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IS1796B (is) *	1993-06-24	2001-12-31	Ab Astra	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5866536A (en) *	1995-03-31	1999-02-02	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5650386A (en) *	1995-03-31	1997-07-22	Emisphere Technologies, Inc.	Compositions for oral delivery of active agents
US6413546B1 (en) *	1999-03-18	2002-07-02	Indena, S.P.A.	Tablets incorporating isoflavone plant extracts and methods of manufacturing them
NZ534409A (en)	1999-04-05	2006-03-31	Emisphere Tech Inc	Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6544553B1 (en) *	1999-12-28	2003-04-08	Watson Pharmaceuticals, Inc.	Dosage forms and methods for oral delivery of progesterone
SK285128B6 (sk) *	1999-12-28	2006-07-07	Zentiva, A. S.	Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy
US7049283B2 (en) *	2000-12-06	2006-05-23	Novartis Ag	Pharmaceutical compositions for the oral delivery of pharmacologically active agents

2004
- 2004-07-09 MX MXPA06000446A patent/MXPA06000446A/es active IP Right Grant
- 2004-07-09 AU AU2004255458A patent/AU2004255458B2/en not_active Ceased
- 2004-07-09 CA CA2529604A patent/CA2529604C/en not_active Expired - Fee Related
- 2004-07-09 JP JP2006518162A patent/JP5032844B2/ja not_active Expired - Fee Related
- 2004-07-09 ES ES04740863T patent/ES2330638T3/es not_active Expired - Lifetime
- 2004-07-09 PL PL04740863T patent/PL1651248T3/pl unknown
- 2004-07-09 US US10/564,259 patent/US20070065505A1/en not_active Abandoned
- 2004-07-09 DE DE602004023093T patent/DE602004023093D1/de not_active Expired - Lifetime
- 2004-07-09 PT PT04740863T patent/PT1651248E/pt unknown
- 2004-07-09 AT AT04740863T patent/ATE442158T1/de active
- 2004-07-09 CN CN2004800174065A patent/CN1809377B/zh not_active Expired - Fee Related
- 2004-07-09 WO PCT/EP2004/007584 patent/WO2005004900A1/en not_active Ceased
- 2004-07-09 EP EP04740863A patent/EP1651248B1/en not_active Expired - Lifetime
- 2004-07-09 BR BRPI0412458-8A patent/BRPI0412458A/pt not_active Application Discontinuation
2008
- 2008-06-04 US US12/132,642 patent/US8435946B2/en not_active Expired - Lifetime
2013
- 2013-04-15 US US13/862,811 patent/US8748383B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
PT1651248E (pt)	2009-11-10
EP1651248B1 (en)	2009-09-09
BRPI0412458A (pt)	2006-10-17
MXPA06000446A (es)	2006-04-07
CA2529604C (en)	2012-05-08
CN1809377A (zh)	2006-07-26
DE602004023093D1 (de)	2009-10-22
WO2005004900A1 (en)	2005-01-20
AU2004255458B2 (en)	2007-09-13
AU2004255458A1 (en)	2005-01-20
JP2009513528A (ja)	2009-04-02
HK1089950A1 (en)	2006-12-15
US20130230593A1 (en)	2013-09-05
JP5032844B2 (ja)	2012-09-26
CA2529604A1 (en)	2005-01-20
CN1809377B (zh)	2010-08-04
EP1651248A1 (en)	2006-05-03
US8435946B2 (en)	2013-05-07
US20080234179A1 (en)	2008-09-25
ATE442158T1 (de)	2009-09-15
US20070065505A1 (en)	2007-03-22
ES2330638T3 (es)	2009-12-14
US8748383B2 (en)	2014-06-10

Publication	Publication Date	Title
PT1651248E (pt)	2009-11-10	Composições farmacêuticas para dose oral compreendendo um agente de administração na forma micronizada
IL155992A0 (en)	2003-12-23	Pharmaceutical compositions for the oral delivery of pharmacologically active agents
WO2008021088A3 (en)	2008-12-24	Salicylanilides enhance oral delivery of therapeutic peptides
GEP20074231B (en)	2007-11-12	Calcitonin gene related peptide receptor antagonists
TWI366460B (en)	2012-06-21	Cannabinoid active pharmaceutical ingredient for improved dosage forms
GEP20074047B (en)	2007-02-26	Pramipexole once-daily dosage form
AR033711A1 (es)	2004-01-07	Composiciones farmaceuticas
TW200517106A (en)	2005-06-01	Sustained release pharmaceutical compositions
MXPA05007609A (es)	2005-09-30	Antagonista de un receptor sensible al calcio.
MX2007015480A (es)	2008-04-29	Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
ZA200709788B (en)	2008-08-27	Cannabinold active pharmaceutical ingredient for Improved dosage forms
MXPA03010054A (es)	2004-04-02	Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
IL157540A0 (en)	2004-03-28	N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
EP1755633A4 (en)	2010-05-12	ORAL ADMINISTRATION OF PEPTIDE PHARMACEUTICAL COMPOSITIONS
EA200600953A1 (ru)	2006-10-27	Дозированные формы торсемида пролонгированного высвобождения
WO2007011958A3 (en)	2007-04-12	Intraoral dosage forms of glucagon
TW200638927A (en)	2006-11-16	Bambuterol and integrin inhibitor combination
ATE460934T1 (de)	2010-04-15	Pharmazeutische zubereitungen von ciprofloxacin
WO2005062722A3 (en)	2005-09-22	Fexofenadine containing pharmaceutical formulation
WO2007035816A3 (en)	2007-06-21	Paroxetine compositions
TW200833375A (en)	2008-08-16	Pharmaceutical compositions
PL1653963T3 (pl)	2007-02-28	Donosowa kompozycja farmaceutyczna pirybedilu
HU0500270D0 (en)	2005-05-30	Pharmacologically active peptide derivatives, process for their preparation and pharmaceutical compositions containing the same
TNSN06299A1 (en)	2007-12-03	Oral matrix formulations comprising licarbazepine
SI1471890T1 (sl)	2006-12-31	Farmacevtska dozirna oblika za dajanje v sluznico